Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter

Cormorant Asset Management increased its Alumis position by 313,645 shares in Q1, an estimated $7.84 million trade that lifted its stake to 3,949,241 shares valued at $87.0 million, or 4.37% of 13F assets. The buy comes after Alumis reported strong Phase 3 psoriasis data, with PASI 90 above 60% and PASI 100 around 40% by Week 24, and management still targeting an NDA filing in Q4 2026. The article is constructive for sentiment around the stock, though the market impact is likely limited to the individual name.

Analysis

Cormorant’s add is more informative as a positioning signal than as a valuation signal: they are pressing exposure after a massive rerate, which usually implies one of two things — either their variant perception on the clinical dataset is still materially above consensus, or they expect the market to keep rewarding clean de-risking until the next binary readout. In a crowded biotech tape, that matters because incremental institutional buying can continue to tighten borrow, lift implied vol, and keep factor flows chasing the same handful of late-stage names.

The second-order winner is likely not the stock itself but the broader TYK2/autoimmune basket. If Alumis can sustain “best-in-class” read-throughs into NDA timing, it raises the bar for competing oral autoimmune assets and may pressure smaller, earlier-stage peers with less differentiated efficacy or weaker cash runways. Conversely, any hiccup in the next two catalysts would likely hit the entire high-multiple autoimmune cohort first, because positioning appears crowded and expectations are now being capitalized well ahead of approval.

The key risk is timing mismatch: the stock has already discounted a lot of good news, while the next few months still require execution rather than narrative. With the balance sheet running well into late 2027, dilution risk is not the near-term issue; the real tail risk is clinical asymmetry — a modest miss on lupus or an NDA delay would likely compress multiple faster than fundamentals deteriorate. This is a name where the next 30-90 days matter more for sentiment, but the next 6-12 months matter more for the terminal outcome.

Key Decisions for Investors

• Hold a tactical long in ALMS only into the next catalyst window; use a tight 10-15% stop because the setup is momentum-supported but extremely consensus-sensitive after the rerate.
• Prefer a call spread over outright equity: buy ALMS 3-6 month calls and finance with a higher strike sale to capture upside into NDA/lupus data while limiting theta if the stock stalls.
• Pair trade: long ALMS / short a weaker, earlier-stage autoimmune developer with less cash runway and no near-term late-stage data; the trade monetizes quality-of-data and balance-sheet differentiation.
• If already long, consider trimming 25-35% into strength ahead of the next readout; the risk/reward has shifted from “mispriced optionality” to “paying up for execution.”
• Watch ERAS for sympathy selloffs on any biotech risk-off day; if the market starts de-rating the basket, that is the signal to reduce all high-beta biotech exposure rather than just ALMS.